Ignite Creation Date:
2024-05-06 @ 4:03 PM
Last Modification Date:
2024-10-26 @ 2:02 PM
Study NCT ID:
NCT04857138
Status:
COMPLETED
Last Update Posted:
2024-02-05
First Post:
2021-04-22
Brief Title:
A Study to Evaluate Safety Pharmacokinetics and Anti-Tumor Activity of RO7300490 as Single Agent or in Combination With Atezolizumab in Participants With Advanced Solid Tumors
Sponsor:
Hoffmann-La Roche
Organization:
Hoffmann-La Roche
Study Overview
Official Title:
An Open-Label Multicenter Dose-Escalation and Expansion Phase I Study to Evaluate Safety Pharmacokinetics And Anti-Tumor Activity of RO7300490 A Fibroblast Activation Protein-α FAP Targeted CD40 Agonist as Single Agent or in Combination With Atezolizumab in Participants With Advanced andor Metastatic Solid Tumors
Status:
COMPLETED
Status Verified Date:
2024-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
A study to evaluate the safety pharmacokinetics and anti-tumor activity of RO7300490 as a single agent or in combination with atezolizumab The study will consist of 3 parts Part 1 Dose-Escalation of RO7300490 as a single agent Part 2 Dose-Escalation of RO7300490 in combination with atezolizumab and Part 3 Dose-Expansion of RO7300490 in combination with atezolizumab in selected cancer types
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 2020-004489-21 | EUDRACT_NUMBER | None | None |